SELECTIONUC · Induction and maintenance
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Feagan BG, et al.
Lancet 2021 · PMID 34090625 (PubMed, opens in a new tab) · doi 10.1016/S0140-6736(21)00666-8 (full paper, opens in a new tab)
| Endpoint | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Difference |
|---|---|---|---|---|
| Induction A: biologic-naive, Week 10 (primary endpoint) | 26.1% | not in this comparison | 15.3% | Difference 10.8% (95% CI 2.1–19.5); P=0.0157 |
| Induction B: biologic-experienced, Week 10 (primary endpoint) | 11.5% | not in this comparison | 4.2% | Difference 7.2% (95% CI 1.6–12.8); P=0.0103 |
| Maintenance, 200 mg, Week 58 · 200 mg responders re-randomised (primary endpoint) | 37.2% | not in this comparison | 11.2% | Difference 26.0% (95% CI 16.0–35.9); P<0.0001 |
| Maintenance, 100 mg, Week 58 · 100 mg responders re-randomised | not in this comparison | 23.8% | 13.5% | Difference 10.4% (95% CI 0.0–20.7); P=0.0420 |
After biologic failure, fewer than 1 in 8 patients reached remission at week 10, even on the effective dose.
Source: Feagan 2021, abstract. Induction results for filgotinib 100 mg are not printed in the abstract (not significantly different from placebo), so they are not drawn.
Structured abstract
BackgroundRemission in UC is often not reached or not kept with existing drugs. SELECTION tested filgotinib, an oral once-daily JAK1-preferential inhibitor, separately in biologic-naive and biologic-experienced patients.
MethodsPhase 2b/3, double-blind, randomised, placebo-controlled: two 11-week induction studies and one maintenance study to week 58 (341 centres, 40 countries). 1,348 patients. Primary endpoint: Clinical remission (Mayo endoscopic, rectal bleeding and stool frequency subscores) at week 10 (induction) and week 58 (maintenance).
ResultsPrimary result. Filgotinib 200 mg: induction A 26.1% vs 15.3% (difference 10.8%, 95% CI 2.1–19.5; P=0.0157); induction B 11.5% vs 4.2% (7.2%, 95% CI 1.6–12.8; P=0.0103); week 58 37.2% vs 11.2% (26.0%, 95% CI 16.0–35.9; P<0.0001).
Take-homeFilgotinib 200 mg induces and maintains remission in UC, but it is not available in Canada; it matters here mainly as evidence for the JAK class.
| Patients | 1,348 |
|---|---|
| Population | Age 18–75 with moderately to severely active UC for at least 6 months. Induction A: biologic-naive (659). Induction B: prior failure of a TNF antagonist or vedolizumab (689). |
| Comparison | Filgotinib 200 mg or 100 mg once daily vs placebo (2:2:1); week-10 responders re-randomised 2:1 to continue filgotinib or switch to placebo |
| Drugs | filgotinib |
| Classes | JAK inhibitor |
| Published | Feagan BG, et al. Lancet 2021;397:2372–84. |
Key points
- Filgotinib 100 mg was not better than placebo at week 10, but was at week 58 (23.8% vs 13.5%; difference 10.4%, 95% CI 0.0–20.7; P=0.0420).
- Remission after prior biologic failure was low in absolute terms (11.5% at week 10 with 200 mg).
- Serious adverse events in induction: 5.0% (100 mg), 4.3% (200 mg) and 4.7% (placebo).
- Filgotinib is not approved in Canada (no listing in the Health Canada Drug Product Database, checked October 2026).
Limitations
- Small absolute benefit in biologic-experienced patients.
- The 100 mg dose failed at induction.
- Not available in Canada.
Commentary
Context. SELECTION is notable for testing biologic-naive and biologic-experienced patients in separate induction studies, which makes the drop in efficacy after prior biologic failure easy to see. For JAK inhibitors available in Canada, see OCTAVE (tofacitinib, PMID 28467869) and U-ACHIEVE and U-ACCOMPLISH (upadacitinib, PMID 35644166).
Later evidence. In Crohn’s disease, filgotinib 200 mg did not meet its week-10 co-primary endpoints of PRO2 remission and endoscopic response in DIVERSITY (PMID 39637881), although both were met at week 58 in induction responders.
Journal club
Design
Phase 2b/3, double-blind, randomised, placebo-controlled: two 11-week induction studies and one maintenance study to week 58 (341 centres, 40 countries). 1,348 patients.
Primary result. Filgotinib 200 mg: induction A 26.1% vs 15.3% (difference 10.8%, 95% CI 2.1–19.5; P=0.0157); induction B 11.5% vs 4.2% (7.2%, 95% CI 1.6–12.8; P=0.0103); week 58 37.2% vs 11.2% (26.0%, 95% CI 16.0–35.9; P<0.0001).
Validity and applicability
- Small absolute benefit in biologic-experienced patients.
- The 100 mg dose failed at induction.
- Not available in Canada.
Where it sits now
Filgotinib 200 mg induces and maintains remission in UC, but it is not available in Canada; it matters here mainly as evidence for the JAK class.
- DIVERSITY (2025): Filgotinib failed its week-10 induction endpoints in Crohn's disease, unlike upadacitinib in its own phase 3 trials, so JAK inhibitors should not be assumed to work equally well in Crohn's disease.
- ASTRO (2026): Guselkumab can be started with subcutaneous 400 mg injections instead of IV infusions, with clear benefit over placebo by week 12.
- RELIEVE UCCD (UC) (2026): Duvakitug, an anti-TL1A antibody, showed a dose-related remission signal in UC in phase 2b; phase 3 trials will decide its place.
- QUASAR (2025): Guselkumab induces and maintains remission in UC, and the follow-up ASTRO trial showed induction can be given subcutaneously.
Questions for discussion
- Filgotinib 100 mg did not beat placebo at induction but did at week 58. How can a dose fail induction yet succeed in a randomised-withdrawal maintenance study?
- After biologic failure, remission was 11.5% vs 4.2%. How would you explain a significant but small absolute benefit to a patient?
- Filgotinib is not available in Canada. How far would you extrapolate these results to other JAK inhibitors, and where would you stop?